Skip to main content
. 2022 Oct;63(10):1523–1530. doi: 10.2967/jnumed.121.263470

FIGURE 3.

FIGURE 3.

Scatterplot of all 18F-FDG–positive lesions (n = 53) measuring ≥ 10 mm (or 15 mm in lymph node) and the lesions’ corresponding 89Zr-DFO-durvalumab uptake. Lesions were distributed over lung (n = 20), lymph nodes (n = 18), local recurrence (n = 8), bone (n = 5), and liver (n = 1).